Journal: Cells

Article Title: A Novel Approach for Glioblastoma Treatment by Combining Apoptosis Inducers (TMZ, MTX, and Cytarabine) with E.V.A. (Eltanexor, Venetoclax, and A1210477) Inhibiting XPO1, Bcl-2, and Mcl-1

doi: 10.3390/cells13070632

Figure Lengend Snippet: ( A ) Apoptosis and dead cell staining of brain slice culture with propidium iodide (dead cells; red), and Caspase 3 (apoptotic cells; green) post-treatment with either TMZ, MTX, and Ara-C and in combination with E.+V.+A. Staining with Hoechst indicates cell nuclei (blue). The left panel consists of merged images from Hoechst-, PI-, and Caspase 3 staining. Staurosporine was used as positive control for induction of apoptosis. ( B ) Quantification of morphological image data from A. Dotted red line indicates the threshold of the control group. Staurosporine was used for positive control. Numbers of PI+ cells/mm 2 are shown in logarithmic scale. One cerebellar slice per treatment was analyzed.

Article Snippet: Venetoclax (HY-15531), A1210477 (HY-12468), and Staurosporine (HY-15141) were purchased from MedChemExpress (Monmouth Junction, NJ, USA).

Techniques: Staining, Slice Preparation, Positive Control, Control

Journal: Journal of Translational Medicine

Article Title: Establishment of a prognostic model based on ER stress-related cell death genes and proposing a novel combination therapy in acute myeloid leukemia

doi: 10.1186/s12967-025-06615-y

Figure Lengend Snippet: The combined use of chaetocin and venetoclax has anti-AML effects both in vitro and in vivo. Schematic showing steps for identifying potential anti-AML drugs on the basis of the CMap database. B Molecular structural formulas of the top 4 small-molecule compounds with CMap scores less than − 90. C, D IC50 values of four small-molecule compounds in U937 and HL60 cells according to the CCK-8 assay. E Twenty-four-hour apoptosis rates of U937 and HL60 cells after treatment with the four individual compounds. F Twenty-four-hour apoptosis rate of U937 and HL60 cells after treatment with chaetocin and venetoclax individually or in combination. G , H Representative bioluminescence images of tumor growth over time in the CDX mouse model (n = 5 per group). I Survival curves of the mice in each different group. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: Cytarabine, doxorubicin, venetoclax, PIK-75, and panobinostat (LBH589) were obtained from Selleck Chemicals.

Techniques: In Vitro, In Vivo, CCK-8 Assay

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Summary of key venetoclax trials in patients with CLL.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques:

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Summary of large, real-world studies of venetoclax trials in patients with CLL.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques:

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Patient case 1: High risk for tumor lysis syndrome (relapsed patient treated with continuous venetoclax). ALC, absolute lymphocyte count; CKD, chronic kidney disease; CLL, chronic lymphocytic leukemia; CT, computerized tomography; HCP, healthcare provider; IGHV, immunoglobulin heavy variable; IHD, ischemic heart disease; IV, intravenous; IRR, infusion-related reaction; L, liter; LN, lymph node; LVEF, left ventricular ejection fraction; mg, milligram; PFS, progression-free survival; PR, partial response; q4w, every 4 weeks; R/R, relapsed/refractory; T2DM, type 2 diabetes mellitus; TLS, tumor lysis syndrome; TP53, tumor protein 53.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques: Lysis, Tomography

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Patient case 2: medium risk for tumor lysis syndrome (treatment-naïve patient treated with fixed-duration venetoclax + obinutuzumab). a Some institutions will give corticosteroids (e.g., dexamethasone, 20 mg) and antihistamines (e.g., diphenhydramine, 25 mg) the night before and morning of the first obinutuzumab infusion, in addition to giving premedications right before the infusion. ALC, absolute lymphocyte count; CLL, chronic lymphocytic leukemia; CrCl, creatinine clearance; CT, computerized tomography; CYP3A, cytochrome P4503A; HCP, healthcare provider; IGHV, immunoglobulin heavy variable; IV, intravenous; IRR, infusion-related reaction; L, liter; LN, lymph node; mg, milligram; SSRI, selective serotonin reuptake inhibitor; TLS, tumor lysis syndrome.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques: Lysis, Tomography

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Patient case 3: low risk for tumor lysis syndrome (relapsed patient treated with continuous venetoclax monotherapy). ALC, absolute lymphocyte count; CLL, chronic lymphocytic leukemia; CrCl, creatinine clearance; HCP, healthcare provider; IGHV, immunoglobulin heavy variable; IRR, infusion-related reaction; IV, intravenous; L, liter; LN, lymph node; mg, milligram; PR, partial response; R/R, relapsed/refractory; TLS, tumor lysis syndrome.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques: Lysis

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Summary of key venetoclax trials in patients with CLL.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques:

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Summary of large, real-world studies of venetoclax trials in patients with CLL.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques:

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Patient case 1: High risk for tumor lysis syndrome (relapsed patient treated with continuous venetoclax). ALC, absolute lymphocyte count; CKD, chronic kidney disease; CLL, chronic lymphocytic leukemia; CT, computerized tomography; HCP, healthcare provider; IGHV, immunoglobulin heavy variable; IHD, ischemic heart disease; IV, intravenous; IRR, infusion-related reaction; L, liter; LN, lymph node; LVEF, left ventricular ejection fraction; mg, milligram; PFS, progression-free survival; PR, partial response; q4w, every 4 weeks; R/R, relapsed/refractory; T2DM, type 2 diabetes mellitus; TLS, tumor lysis syndrome; TP53, tumor protein 53.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques: Lysis, Tomography

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Patient case 2: medium risk for tumor lysis syndrome (treatment-naïve patient treated with fixed-duration venetoclax + obinutuzumab). a Some institutions will give corticosteroids (e.g., dexamethasone, 20 mg) and antihistamines (e.g., diphenhydramine, 25 mg) the night before and morning of the first obinutuzumab infusion, in addition to giving premedications right before the infusion. ALC, absolute lymphocyte count; CLL, chronic lymphocytic leukemia; CrCl, creatinine clearance; CT, computerized tomography; CYP3A, cytochrome P4503A; HCP, healthcare provider; IGHV, immunoglobulin heavy variable; IV, intravenous; IRR, infusion-related reaction; L, liter; LN, lymph node; mg, milligram; SSRI, selective serotonin reuptake inhibitor; TLS, tumor lysis syndrome.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques: Lysis, Tomography

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Patient case 3: low risk for tumor lysis syndrome (relapsed patient treated with continuous venetoclax monotherapy). ALC, absolute lymphocyte count; CLL, chronic lymphocytic leukemia; CrCl, creatinine clearance; HCP, healthcare provider; IGHV, immunoglobulin heavy variable; IRR, infusion-related reaction; IV, intravenous; L, liter; LN, lymph node; mg, milligram; PR, partial response; R/R, relapsed/refractory; TLS, tumor lysis syndrome.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques: Lysis

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Summary of key venetoclax trials in patients with CLL.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques:

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Summary of large, real-world studies of venetoclax trials in patients with CLL.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques:

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Patient case 1: High risk for tumor lysis syndrome (relapsed patient treated with continuous venetoclax). ALC, absolute lymphocyte count; CKD, chronic kidney disease; CLL, chronic lymphocytic leukemia; CT, computerized tomography; HCP, healthcare provider; IGHV, immunoglobulin heavy variable; IHD, ischemic heart disease; IV, intravenous; IRR, infusion-related reaction; L, liter; LN, lymph node; LVEF, left ventricular ejection fraction; mg, milligram; PFS, progression-free survival; PR, partial response; q4w, every 4 weeks; R/R, relapsed/refractory; T2DM, type 2 diabetes mellitus; TLS, tumor lysis syndrome; TP53, tumor protein 53.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques: Lysis, Tomography

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Patient case 2: medium risk for tumor lysis syndrome (treatment-naïve patient treated with fixed-duration venetoclax + obinutuzumab). a Some institutions will give corticosteroids (e.g., dexamethasone, 20 mg) and antihistamines (e.g., diphenhydramine, 25 mg) the night before and morning of the first obinutuzumab infusion, in addition to giving premedications right before the infusion. ALC, absolute lymphocyte count; CLL, chronic lymphocytic leukemia; CrCl, creatinine clearance; CT, computerized tomography; CYP3A, cytochrome P4503A; HCP, healthcare provider; IGHV, immunoglobulin heavy variable; IV, intravenous; IRR, infusion-related reaction; L, liter; LN, lymph node; mg, milligram; SSRI, selective serotonin reuptake inhibitor; TLS, tumor lysis syndrome.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques: Lysis, Tomography

Journal: Cancers

Article Title: Venetoclax Initiation in Chronic Lymphocytic Leukemia: International Insights and Innovative Approaches for Optimal Patient Care

doi: 10.3390/cancers16050980

Figure Lengend Snippet: Patient case 3: low risk for tumor lysis syndrome (relapsed patient treated with continuous venetoclax monotherapy). ALC, absolute lymphocyte count; CLL, chronic lymphocytic leukemia; CrCl, creatinine clearance; HCP, healthcare provider; IGHV, immunoglobulin heavy variable; IRR, infusion-related reaction; IV, intravenous; L, liter; LN, lymph node; mg, milligram; PR, partial response; R/R, relapsed/refractory; TLS, tumor lysis syndrome.

Article Snippet: M.A.A. is an employee of the Walter and Eliza Hall Institute that receives milestone payments in relation to venetoclax; has received honoraria from AbbVie, Janssen, AstraZeneca, BeiGene, Roche, Novartis, Gilead Sciences, CSL, Takeda.

Techniques: Lysis